|
Acadia Pharmaceuticals Inc., a biopharmaceutical company is advancing breakthroughs in neuroscience to elevate life, announced that the US District Court for the District of Delaware ruled in favour of Acadia regarding its ‘721 formulation patent for Nuplazid (pimavanserin), Acadia’s drug for the treatment of Parkinson’s disease psychosis. In this order, the Court ruled in favour of Acadia on both infringement and validity arguments in its formulation patent litigation against Aurobindo Pharma Limited and other ANDA (Abbreviated New Drug Application) filers.
“We are very pleased with today’s decisive ruling in our favour, which provides patent protection for Nuplazid 34 mg capsule formulation into 2038,” said Catherine Owen Adams, chief executive officer. “This result highlights Acadia’s dedication to safeguarding our advancements in therapies for conditions with significant unmet medical needs.”
Acadia is advancing breakthroughs in neuroscience to elevate life. Since its founding the company have been working at the forefront of healthcare to bring vital solutions to people who need them most.
|